Hypoxic BMSC-derived exosomes-induced mitophagy quenches intestinal inflammation via HIF-1α/BNIP3 pathway Authors: Feng Zhu, Jingbo Wang, Yuyi Yuan, Chunzhu Wei, Fei Gao, Xingxing Liu, Jingjing Li, Zaifeng Yi, Lijuan Zhang, Heng Fan Published: 2025 ABSTRACT AbstractThe use of hypoxia-preconditioned exosomes (HP-Exos) to modulate intestinal immunity in ulcerative colitis (UC) represents a promising therapeutic strategy. However, the effects of hypoxic preconditioning on exosomes derived from bone marrow mesenchymal stem cells (BMSCs) and the underlying mechanisms in UC treatment remain inadequately understood. This study sought to elucidate the regulatory roles and molecular mechanisms of HP-Exos in the context of UC. HP-Exos were isolated from BMSCs and characterized. We employed hypoxia-inducible factor 1α (HIF-1α)-silenced lentivirus-interfered HP-Exos to assess their effects in both in vivo and in vitro models. A series of experiments were conducted to evaluate the effects of HP-Exos on mitophagy, oxidative stress, and apoptosis in HT-29 cells and colonic tissues and to comprehensively analyze the immunoprotective mechanisms of HP-Exos. The results demonstrated that HP-Exos enhanced mitophagy, inhibited reactive oxygen species (ROS) accumulation and apoptosis in HT-29 cells and colon tissues, and upregulated the expression of Bcl-2 19-kDa interacting protein 3 (BNIP3), a downstream effector of HIF-1α. Conversely, HIF-1α knockdown markedly reversed the increase in mitophagy and the inhibition of apoptosis. Our findings indicate that HP-Exos protect against DSS-induced colitis by mitigating apoptosis and ROS production through HIF-1α-BNIP3-mediated mitophagy.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-025-32293-3.Keywords: Ulcerative colitis, Exosomes, Hypoxia, Hypoxia-inducible factor 1α, MitophagySubject terms: Cell biology, Gastroenterology, Stem cells Introduction Ulcerative colitis (UC) is a common disease of the digestive system that is often caused by genetic or immune factors, gut microbiota imbalance and metabolic disorders1. UC is an easily diagnosed clinical disease; however, effective treatments for this disease are lacking. In mainland China, the incidence ratio of UC is approximately 0.94, and the prevalence has increased significantly over time2. Because of the complex pathogenesis of UC, there is currently no cure. Patients with UC symptoms are prone to recurrent attacks, which seriously damage the physical and mental health of patients and reduce their quality of life. Therefore, further study of the mechanism of UC and the development of a safe and effective therapeutic strategy are imperative. Mitochondria are thought to be essential for maintaining cell survival and physiological functions because they are the main source of ATP in cells3. Dysfunctional mitochondria can lead to abnormal cell function and even apoptosis; mitophagy can selectively remove these damaged mitochondria and restore the stability of the intracellular environment4. Studies have shown that the mitochondrial protein Bcl-2 19-kDa interacting protein 3 (BNIP3) plays a crucial role in mitophagy5. On the one hand, the dysregulation of mitochondrial activity leads to programmed cell death; on the other hand, it leads to the production of a large number of byproducts and reactive oxygen species (ROS), which can cause damage to cellular DNA and proteins6. Notably, mitophagy plays an important role in the pathogenesis of UC7. Moreover, a growing number of studies have revealed that oxidative stress and increased ROS in intestinal epithelial cells (IECs) are considered two hallmarks of the acute phase of UC8. Therefore, mitochondrial damage and dysfunction in IECs affect the pathogenesis of UC through various mechanisms. Hypoxia-inducible factor 1α (HIF-1α) has been shown to drive mitophagy in a stress environment9; although many other mitochondrial proteins are present, only BNIP3 can be induced by HIF-1α to cause mitophagy10. HIF-1α has been shown to induce BNIP3 to mediate mitophagy in a variety of cell types, including tubular cells11, nucleus pulposus cells12, and H9C2 cardiomyocytes13. However, the mechanism of HIF-1–BNIP3 activity in UC IECs remains unclear. Mesenchymal stem cells (MSCs) regulate immune balance, promote mitophagy, and reduce ROS accumulation and antiapoptotic activity, all of which are beneficial for the treatment of many diseases14. Interestingly, studies have shown that MSCs play a therapeutic role mainly through paracrine exosomes15. Exosomes can carry miRNAs and proteins, which play important roles in intercellular communication16. Exosome therapy can not only exploit the therapeutic advantages of MSC transplantation but also overcome its therapeutic limitations17; for example, exosomes have the advantages of strong targeting ability and low immunogenicity18. Previous studies have confirmed that exosomes derived from MSCs can treat UC through the regulation of immune activity, antioxidation activity and apoptosis19,20. In addition, hypoxia can upregulate the expression of HIF-1α in MSCs and enhance its therapeutic effect21. Exosomes derived from MSCs pretreated with hypoxia (HP-Exos) have been studied in many diseases, such as ischemic heart disease22 and spinal cord injury23. Studies have shown that HIF overexpression in human MSCs promoted healing in a TNBS-induced mouse colitis model by preserving intestinal mucosa architecture and altering the ratio of Mφ1/Mφ2 infiltration24. Interestingly, our previous studies also revealed that HP-Exos inhibited ROS accumulation and DNA damage in UC25. However, how HP-Exos regulate ROS accumulation in IECs and their relationship with mitophagy are unclear. Based on the results of previous studies, this study further demonstrated that HP-Exos induce mitochondrial autophagy through HIF-1 A/BNIP3, thereby inhibiting the accumulation of ROS and DNA damage in cells and alleviating intestinal inflammation. The specific mechanism through which HP-Exos regulate mitophagy and its potential role in UC IECs remain largely unknown. In this study, we performed in vitro and in vivo experiments to investigate whether HP-Exos play a protective role by inducing HIF-1α/BNIP3-mediated mitophagy in UC. Materials and methods Cell culture and animal models The human colonic cell line HT-29 from the American Type Culture Collection (ATCC, Manassas, VA, USA) was cultured in DMEM (HyClone, USA) supplemented with 10% fetal bovine serum (FBS, Gibco, USA) and 1% penicillin/streptomycin (Biosharp, Shanghai, China) in an incubator with 5% CO2 at 37 °C. Previous studies have revealed that LPS can activate mitophagy26. HT-29 cells were divided into six groups: Ctrl, LPS, HP-Exos, HP-siHIF-1α-Exos, 3-methyladenine (3-MA, an autophagy inhibitor), and HP-Exos + 3-MA. Except the Ctrl group, the other groups were treated with LPS (1 µg/ml) for 24 h to establish the model, followed by treatment with the corresponding exosomes (10 µg) in the HP-Exos, HP-siHIF-1α-Exos and HP-Exos + 3-MA groups for 24 h. Moreover, the 3-MA and HP-Exos + 3-MA groups were incubated with 5 mM 3-MA for 24 h. Cells or supernatants were then collected. Forty-eight male Sprague‒Dawley (SD) rats (180–200 g) were purchased from the Experimental Animal Center of Huazhong University of Science and Technology (HUST, Wuhan, China) and housed in a controlled environment (specific pathogen-free conditions). The animal protocols were approved by the Institutional Animal Care and Use Committee (IACUC) of HUST. We confirm that all methods were carried out in accordance with the relevant guidelines and regulations and were performed in accordance with the ARRIVE guidelines. In accordance with a previous protocol25, the rats were randomly divided into six groups (n = 8/group), and different treatments were applied daily as follows (Table 1): Table 1Animal modeling and drug administration process. Animal modeling and drug administration process. Normal Group: The rats were given normal water. PBS was injected into the tail vein and intraperitoneally. DSS Group: 5% DSS (36–50 kDa; MP Biomedicals, France) was given to the rats freely for 7 days in the drinking water. PBS was injected into the tail vein and intraperitoneally. HP-Exos Group: Rats in the DSS Group were treated with 100 µg of HP-Exos twice a week. PBS was injected intraperitoneally. HP-siHIF-1α-Exos Group: Rats in the DSS Group were treated with 100 µg of HP-siHIF-1α-Exos twice a week. PBS was injected intraperitoneally. 3-MA Group: Rats in the DSS Group were treated with 3-MA (10 mg/kg, i.p.) daily for 7 days. PBS was injected into the tail vein. HP-Exos + 3-MA Group: Rats in the HP-Exos Group were treated with 3-MA (10 mg/kg, i.p.) daily for 7 days. PBS was injected into the tail vein. Body weight and fecal characteristics of the rats were monitored every day. All the animals were anesthetized using sodium pentobarbital (30 mg/kg, intraperitoneally) on the 15th day. The anesthetized rats were placed on a laboratory bench. The operator held the rat’s tail with their right hand, pressed the head and neck of the rat with their left hand, and pulled the tail backward and upward with their right hand. The operator felt that the rat’s spine broke and that the rat died instantly. Blood was extracted from the eyeballs, and the colon tissues were removed for measurement and image capture and then washed in precooled phosphate-buffered saline (PBS). Some of the colon tissue was fixed in paraformaldehyde, some was fixed in electron microscopy fixative, some was used to extract IECs, and the rest was frozen at − 80 °C for later use. BMSC culture and hypoxia treatment Primary BMSCs were extracted from the humerus and femur bones of SD (50 g) rats27. BMSCs were cultured in DMEM/F12 (HyClone, USA) supplemented with 10% FBS and 1% penicillin/streptomycin and incubated at 37 °C with 5% CO2 and an oxygen concentration of 21% O2 (normal oxygen) or 1% O2 (hypoxic oxygen). The cell culture supernatant was collected for exosome isolation. Transfection of BMSCs with HIF-1α Silencing lentivirus When the P2 BMSCs reached 20–40% confluence in the T25 culture flask, transfection was performed. The cells were transfected with HIF-1α silencing lentivirus or negative control lentivirus (Genechem, Shanghai, China) according to previous methods25. To confirm the knockdown of HIF-1α, we extracted protein from BMSCs and analyzed it using Western blotting. Isolation and characterization of exosomes HP-Exos and HP-siHIF-1α-Exos were harvested using total exosome isolation reagent (Life Technologies, Shanghai, China). Serum-free medium was added to the BMSCs, the medium was collected after 24 h and centrifuged at 500, 3000, and 16,000 × g for 10, 30, and 20 min at 4 °C, and the supernatant was transferred to a new tube after each centrifugation. The specific collection methods used are the same as those used in previous studies25. The exosomes were freshly suspended in PBS and stored at − 80 °C for subsequent investigation. The diameter distribution and morphology of Exos and HP-Exos were examined using nanoparticle tracking analysis (NTA) (NanoSight, Malvern, UK) (ZetaView 8.04.02) and transmission electron microscopy (TEM) (Tecnai G2 20TWIN, FEI, USA), respectively. The expression levels of the exosomal marker proteins TSG101, CD9 and CD63 were measured by Western blotting. IEC isolation The colon was opened longitudinally, washed in RPMI 1640 medium, and cut into 5 mm pieces. Afterward, the pieces were incubated in extraction buffer (5 mM EDTA, 2 mM DTT, and 10% fetal bovine serum in PBS) with continuous rapid stirring at 37 °C for 30 min. The tissue suspension was filtered rapidly through a 40 μm strainer to remove debris and centrifuged at 2,000 rpm at 4 °C for 5 min. Pelleted cells were suspended in 40%/70% isotonic Percoll (Sigma, USA) and centrifuged at 2,000 RPM at room temperature for 20 min. The supernatants contained an enriched IEC population26. Histopathology Colonic tissues (samples selected randomly across regions) were fixed and embedded, after which the sections were stained with periodic acid-Schiff (PAS) and hematoxylin and eosin (H&E) for histological analysis. Mitochondrial isolation from cells and tissues Mitochondria were isolated using a tissue or cell mitochondrial isolation kit (Beyotime, Shanghai, China). Briefly, the tissues or cells were homogenized in a mitochondrial isolation reagent to lyse the cells. The supernatant was collected by centrifugation at 1000 × g for 5 min at 4 °C. After the samples were centrifuged at 11,000 g and 4 °C for 10 min, the mitochondria had precipitated. Cytoplasmic and mitochondrial protein fractions were then analyzed by BCA to determine protein concentrations. Quantitative real-time polymerase chain reaction (qRT‒PCR) Total RNA was extracted using TRIzol. The RNA was then reverse transcribed into cDNA according to the protocol provided for the reverse transcription reagent (Vazyme, Nanjing, China). Next, the cDNA was amplified using a kit (Vazyme) and finally analyzed to confirm changes in gene expression. The sequences of the primers used are listed in Table 2. The RNA was treated with DNase I (Vazyme) to eliminate potential genomic DNA contamination. The absence of gDNA was confirmed by running a no-reverse transcription control (No-RT) for each RNA sample during the qPCR setup. Gene expression levels were normalized to those of the reference gene (LPS) and are presented as the fold change relative to that of the control group, which was calculated using the 2^(−ΔΔCq) method. Table 2Primer sequences used for quantitative Real-time PCR.Primer sequences used for Quantitative Real-time PCRGene nameForward sequence (5’ to3’)Reverse sequence (5’ to 3’)hIL-1βATGATGGCTTATTACAGTGGCAAGTCGGAGATTCGTAGCTGGAhTNF-αGAGGCCAAGCCCTGGTATGCGGGCCGATTGATCTCAGChIL-8ACTGAGAGTGATTGAGAGTGGACAACCCTCTGCACCCAGTTTTChGAPDHTCAAGGCTGAGAACGGGAAGCGCCCCACTTGATTTTGGAG Primer sequences used for quantitative Real-time PCR. Western blot (WB) Total protein was extracted from cells, tissues and exosomes following a routine procedure. After the protein samples were fractionated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis, they were blocked with 5% skim milk for 90 min and then incubated with primary antibodies (anti-HIF-1α, 1:1000, A11945, Ab5683, ABclonal; anti-LC3B, 1:1000, A5601, ABclonal; anti-P62, 1:1500, A7758, ABclonal; anti-Bcl-2, 1:400, A11313, ABclonal; anti-caspase-3, 1:1000, A19654, ABclonal; anti-Bax, 1:1000, A18642, ABclonal; and anti-β-actin, 1:100000, AC026, ABclonal) overnight at 4 °C on a shaker. After the membranes were washed with TBST the next day, they were incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies for 2 h at room temperature. Specific proteins were observed and compared using chemical hypersensitive luminescence reagents A and B (Servicebio, Wuhan, China). Immunofluorescence staining For cell immunofluorescence, HT-29 cells in 48-well plates were fixed with 4% paraformaldehyde and permeabilized with 0.5% Triton X-100 for 20 min at room temperature. They were then blocked with goat serum and incubated with primary antibody (anti-LC3B) overnight, followed by incubation with fluorescent secondary antibodies. Finally, a DAPI-containing anti-fluorescence quencher was added to the cells for observation under a fluorescence microscope. For tissue, the slices were dewaxed in water supplemented with a transparent agent, anhydrous ethanol, 95% ethanol and 85% ethanol. Antigen repair was performed in citrate solution, followed by blocking, primary antibody incubation, secondary antibody incubation, and finally sealing for observation. Mitochondrial membrane potential Mito-tracker Red CMXRos can specifically label bioactive mitochondria in cells and can be used to detect apoptosis by detecting changes in mitochondrial membrane potential. First, MitoTracker was used to dilute the cells to a working concentration of 100 nM, and then, the HT-29 cells or IECs were incubated with MitoTracker at 37 °C for 30 min in the dark. If it was necessary to observe the cells under a fluorescence microscope, the cells were fixed and stained with nuclei; otherwise, the cells could be directly detected by flow cytometry. Transmission electron microscopy Colon tissue blocks (1 mm3) and HT-29 cells were fixed in 2.5% glutaraldehyde. After fixation with 2% osmium tetroxide, the samples were dehydrated in a series of graded ethanol solutions and propylene oxide, and then the samples were embedded in epoxy resin. The sections were double stained with uranyl acetate and lead citrate. The sections then were observed under a transmission electron microscope. ELISA and measurement of oxidative stress The concentrations of IL-1β, TNF-α and IL-8 in HT-29 cells were determined by ELISA. SOD and GSH (Nanjing Jiancheng Bioengineering Institute, China) levels in rat serum and HT-29 cells were determined using commercial kits according to the manufacturer’s instructions. Flow cytometry analysis DCFH-DA (Beyotime, Haimen, China) was used to label the ROS. In general, the cells were incubated with a probe containing 10 µmol/L DCFH-Da at 37 °C for 20 min in the dark, after which the cells were washed with RPMI 1640 medium to completely remove the DCFH-Da that did not enter the cells. Apoptotic IECs and HT-29 cells were quantified using an apoptosis detection kit (BD, Franklin Lakes, USA). The cells were resuspended in 1× binding buffer and incubated with PE-annexin V/7-ADD antibodies. The proportions of ROS-producing and apoptotic IECs and HT-29 cells were detected by flow cytometry (BD Biosciences, USA). Statistics The data are shown as the mean ± standard deviation. GraphPad Prism 7.0 software (GraphPad Prism Software) was used for statistical analysis and to create the graphs. Two groups were analyzed with an unpaired two-tailed Student’s t test. One-way ANOVA was used for comparisons between multiple groups, and the Bonferroni post hoc correction was used for pairwise comparisons within groups. P < 0.05 indicated statistical significance. Prior to the parametric statistical analysis, the data were screened for underlying assumptions. Normality was tested for each group using the Shapiro‒Wilk test, with a significance level of α = 0.05. The homogeneity of variance across groups was evaluated using Levene’s test. Based on these results, the appropriate statistical tests were selected: standard parametric tests when assumptions were met, nonparametric alternatives when normality was violated, and robust tests (Welch’s ANOVA) when only the assumption of homogeneity was violated. Results Isolation and characterization of BMSCs and HP-Exos The BMSCs were fusiform and distributed in a vortex under the microscope (Fig. 1A). In addition, by flow cytometry, the percentage of cells positive for both CD90 and CD29 on the BMSC surface was greater than 99%, and the percentage of cells negative for both CD11b and CD45 was greater than 99% (Fig. 1B). Characterization of rat BMSCs and HP-Exos. (A) Representative image of Passage 2 (P2) BMSCs. Original magnification,×40. Scale bar: 200 μm. (B)Flow cytometry characterization of P3 BMSCs. (C)Transmission electron microscopy (TEM) analysis of HP-Exos. Scale bar: 200 nm. (D)Nanoparticle tracking analysis (NTA) of the HP-Exos. (E)Western blotting (WB) analysis of Exos specific marker proteins CD9, TSG101, and CD63 in BMSCs and HP-Exos. (F)Detection of exosomal HIF-1α protein expression levels HP-Exos and HP-siHIF-1α-Exos by WB. HP-Exos were identified by TEM, NTA and WB. TEM revealed that the HP-Exos exhibited a typical teato-like structure with a bilayer membrane, with diameters ranging from 50 to 200 nm, and NTA showed a similar size distribution (average of 141.3 nm) (Fig. 1C, D). Additionally, WB revealed that CD9, CD63 and TSG101 were enriched on the surfaces of the HP-Exos (Fig. 1E). HIF-1α is continuously produced and degraded under normoxic conditions, whereas under hypoxic conditions, decreased ubiquitination of HIF-1α results in a rapid increase in the concentration of HIF-1α in cells. The protein expression of HIF-1α in the HP-Exos was evaluated by WB. The results verified that the content of HIF-1α in the HP-Exos was greater than that in the HP-siHIF-1α-Exos (Fig. 1F). HIF-1α siRNA inhibited HP-Exos-induced HIF-1α expression. Studies have shown that hypoxia pretreatment of MSCs can prevent the degradation of HIF-1α, leading to the accumulation of HIF-1α in cells and its entry into exosomes21. Consequently, HIF-1α-enriched exosomes are believed to represent a more effective treatment for UC. HP-Exos promote LPS-induced mitophagy in HT-29 cells Compared with LPS treatment alone, treatment with HP-Exos increased the LC3-II/LC3-I and HIF-1α protein ratios and decreased p62 expression in HT-29 cells (Fig. 2A and B). Next, to confirm the effect of HP-Exos on mitophagy, we detected the mitochondrial membrane potential and LC3 fluorescence intensity and observed mitochondria and mitophagosomes in HT-29 cells by TEM. The results indicated that the HP-Exos increased the LC3 fluorescence and mitochondrial membrane potential induced by LPS (Fig. 2C and D). Additionally, HP-Exos increased the number of mitophagosomes in LPS-induced HT-29 cells (Fig. 2E). Here, our study revealed that HP-Exos promote LPS-induced mitophagy in HT-29 cells. HP-Exos promote mitophagy in HT-29 cells induced by LPS. (A and B) The expression of HIF-1α, LC3 and P62 proteins were measured by WB in each group of HT-29 cells. (C)LC3 immunofluorescence images and fluorescence intensity statistics in HT-29 cells. Scale bar: 50 μm. (D)Mitochondrial membrane potential fluorescence images and fluorescence intensity statistics in HT-29 cells. Scale bar: 50 μm. (E)Mitochondria (the white arrows) and mitophagosomes (the black arrows) were observed by TEM. Scale bar: 5.0 μm and 2.0 μm. All data are means ± SDs (n = 3). *P<0.05, **P<0.01 versus the control group. Silencing HIF-1α in HP-Exos inhibits mitophagy in HT-29 cells To assess the important role of HIF-1α in the regulation of mitophagy by HP-Exos, we silenced HIF-1α in HP-Exos. Compared with the HP-Exos, the HP-siHIF-1α-Exos significantly decreased the protein expression levels of HIF-1α, BNIP3 and LC3-II/LC3-I but increased the level of P62 (Fig. 3A and B). Furthermore, silencing HIF-1α markedly reduced the increases in LC3 fluorescence (Fig. 3C) and mitochondrial membrane potential (Fig. 3D) and the increase in the number of mitophagosomes in HT-29 cells induced by HP-Exos (Fig. 3E). Silencing HIF-1α in HP-Exos inhibites mitophagy in HT-29 cells. (A and B) The expression of HIF-1α, BNIP3, LC3 and P62 proteins were measured by WB in each group of HT-29 cells. (C)LC3 immunofluorescence images and fluorescence intensity statistics in HT-29 cells. Scale bar: 50 μm. (D)Mitochondrial membrane potential fluorescence images and fluorescence intensity statistics in HT-29 cells. Scale bar: 50 μm. (E)Mitochondria (the white arrows) and mitophagosomes (the black arrows) were observed by TEM. Scale bar: 5.0 μm and 2.0 μm. All data are means ± SDs (n = 3). *P<0.05, **P<0.01, #P<0.001 versus the control group. To further investigate whether autophagy plays a key role in the ability of HP-Exos to protect cells, we pretreated cells with an autophagy inhibitor (3-MA). We found that 3-MA inhibited the autophagy of damaged mitochondria in cells induced by LPS. However, HP-Exos treatment not only protected mitochondria from damage but also increased the number of mitophagosomes. In addition, 3-MA reversed the therapeutic effects of the HP-Exos (Fig. 4A). Moreover, the results revealed that 3-MA significantly inhibited HIF-1α, BNIP3, and LC3-II/LC3-I expression and promoted P62 expression in HT-29 cells induced by LPS. Moreover, 3-MA reversed the increases in HIF-1α, BNIP3, and LC3-II/LC3-I expression and the decrease in P62 expression induced by HP-Exos (Fig. 4B–F). Based on the above results, we concluded that HP-Exos may promote LPS-induced mitophagy in HT-29 cells through HIF-1α/BNIP3. 3-MA inhibits mitophagy promoted by HP-Exos in HT-29 cells. (A)Mitochondria (the white arrows) and mitophagosomes (the black arrows) were observed by TEM. Scale bar: 5.0 μm and 2.0 μm. (B-F) The expression of HIF-1α, BNIP3, LC3 and P62 proteins were measured by WB in each group. All data are means ± SDs (n = 3). *P<0.05, **P<0.01, #P<0.001 versus the control group. HP-Exos rescue ROS accumulation and apoptosis in HT-29 cells Because mitophagy is closely related to ROS and apoptosis, we detected the expression levels of apoptotic proteins, related oxidative stress indicators and inflammatory factors. Compared with HP-siHIF-1α-Exos, HP-Exos promoted the expression of the antiapoptotic protein Bcl-2 and inhibited the expression of the proapoptotic proteins BAX and cleaved caspase-3 (C-caspase3) (Fig. 5A and B). Moreover, HP-Exos significantly reduced early apoptosis in HT-29 cells (Fig. 5C). Interestingly, we found that HP-Exos reversed the accumulation of ROS and the decreases in the levels of SOD and GSH induced by HP-siHIF-1α-Exos (Fig. 5D–F). In addition, IL-1β and TNFα protein levels were reduced by HP-Exos, as determined by ELISA (Fig. 5G and H). Moreover, compared with those in the HP-siHIF-1α-Exos group, the mRNA expression levels of IL-1β, TNFα and IL-8 in the HP-Exos group were decreased (Fig. 5I). Similarly, we explored the effects of 3-MA on ROS accumulation and apoptosis in cells. The results revealed that 3-MA considerably increased apoptosis and that ROS level of ROS in HP-Exos was reduced in HT-29 cells (Fig. 6A–H). Notably, HP-Exos can rescue ROS accumulation and apoptosis in HT-29 cells via mitophagy. HP-Exos impede ROS accumulation and apoptosis in HT-29 cells. (A and B) The expression of Bcl-2, BAX and Cleaved caspase-3 proteins were measured by WB. The effects of apoptosis (C) and ROS production (D) were analysed using flow cytometry in HT-29 cells. (E-H) The contents of SOD, GSH, IL-1β and TNF-α in each group were determined by ELISA. (I) mRNA expression levels of IL-1β, TNF-α and IL-8 were detected by qRT-PCR. All data are means ± SDs (n = 3). *P<0.05, **P<0.01, #P<0.001 versus the control group. 3-MA promotes cell apoptosis and ROS production reduced by HP-Exos in HT-29 cells. (A and B)Cell apoptosis were analysed by flow cytometry. (C-F) The expression of Bcl-2, BAX and Cleaved caspase-3 proteins were measured by WB. (H)ROS accumulation were analysed using flow cytometry. All data are means ± SDs (n = 3). *P<0.05, **P<0.01, #P<0.001 versus the control group. HP-Exos improve pathological symptoms in rats with DSS-induced colitis Compared with DSS, HP-Exos improved acute active colitis in rats, as indicated by the DAI score (Fig. 7A), body weight (Fig. 7B) and colon length (Fig. 7C and D), but significantly reduced histological inflammation and glandular destruction of the colonic tissue and alleviated goblet cell injury (Fig. 7E and F). These findings indicated that HP-Exos improved pathological symptoms in rats with DSS-induced colitis. HP-Exos improve the pathological symptoms in DSS-induced colitis rats. (A)DAI score of rats. (B)Changes in body weight. Representative picture (C) and length quantification (D) of colon from each group. (E)Histopathological changes in colon tissues analyzed by hematoxylin and eosin (HE) staining. Original magnification,×40(upper) and ×200(lower). Scale bars: 200 μm and 50 μm. (F)PAS staining of goblet cells in colon tissues. Original magnification, ×40(upper) and ×200(lower). Scale bars: 200 μm and 50 μm. All data are means ± SDs (n = 6). *P<0.05, **P<0.01, #P<0.001 versus the control group. HP-Exos enhance DSS-induced mitophagy through HIF-1α/BNIP3 We then evaluated whether HIF-1α is involved in the main role of HP-Exos in UC treatment and its relationship with mitophagy. Compared with DSS treatment, HP-Exos treatment considerably increased the protein expression levels of HIF-1α and BNIP3, whereas treatment with HP-siHIF-1α-Exos reversed these changes. More importantly, HIF-1α knockdown markedly prevented the increase in the mitophagy marker LC3II and decreased the mitophagy-related protein p62 induced by HP-Exos (Fig. 8A and B). Furthermore, in contrast with the effects of HP-siHIF-1α-Exos, HP-Exos markedly increased the LC3 fluorescence intensity (Fig. 8C and D) and mitochondrial membrane potential (Fig. 8E) in the colonic tissue. HP-Exos inhibited mitochondrial damage caused by DSS, such as linear swelling, ridge fracture, and membrane blurring (Fig. 8F). HP-Exos enhance DSS-induced mitophagy through HIF-1α/BNIP3. (A and B) The expression of HIF-1α, BNIP3, LC3 and P62 proteins were measured by WB in each group of colon tissues. (C and D) LC3 immunofluorescence images and fluorescence intensity statistics. Scale bar: 50 μm. (E)Mitochondrial membrane potential of IECs was detected by flow cytometry. (F)Mitochondria were observed by TEM. Scale bar: 1.0 μm and 500 nm. All data are means ± SDs (n = 3). *P<0.05, **P<0.01, #P<0.001 versus the control group. 3-MA inhibited DSS-induced mitochondrial damage repair in colon tissues. Interestingly, HP-Exos markedly inhibited DSS-induced mitochondrial damage, whereas 3-MA reversed this effect (Fig. 9A). Moreover, 3-MA reversed the increases in HIF-1α, BNIP3, and LC3-II/LC3-I expression and the decrease in P62 expression induced by HP-Exos in colon tissues (Fig. 9B–F). These results indicate that HP-Exos enhance DSS-induced mitophagy through the HIF-1α/BNIP3 pathway. 3-MA inhibits mitophagy promoted by HP-Exos in DSS-induced colitis IECs. (A)Mitochondria were observed by TEM. Scale bar: 1.0 μm and 500 nm. (B-F) The expression of HIF-1α, BNIP3, LC3 and P62 proteins were measured by WB in each group. All data are means ± SDs (n = 3). *P<0.05, **P<0.01, #P<0.001 versus the control group. HP-Exos decrease ROS accumulation and apoptosis in IECs through mitophagy ROS accumulation and apoptosis related to mitophagy were detected. Our study revealed that HP-Exos markedly increased the expression of the antiapoptotic protein Bcl-2 and inhibited the expression of the proapoptotic proteins BAX and C-caspase3 in intestinal epithelial cells (Fig. 10A and B). In the same way, it also inhibited the early apoptosis of IECs (Fig. 10C). In contrast, HIF-1α knockdown reversed the effects of the HP-Exos on the expression of apoptosis-related proteins and the proportion of early apoptotic cells. Moreover, compared with HP-siHIF-1α-Exos, HP-Exos significantly decreased ROS accumulation and increased the levels of SOD and GSH in IECs (Fig. 10D–F). Additionally, 3-MA markedly increased the number of apoptotic and ROS-producing cells in the colon in the HP-Exos-treated group (Fig. 11A–H). These results demonstrate that HP-Exos decrease ROS accumulation and apoptosis in IECs through mitophagy. HP-Exos decrease ROS accumulation and apoptosis in IECs. (A and B) The expression of Bcl-2, BAX and Cleaved caspase-3 proteins were measured by WB. The effects of apoptosis (C) and ROS production (D) were analysed using flow cytometry in IECs. (E and F) The contents of SOD and GSH were determined by ELISA. All data are means ± SDs (n = 3). *P<0.05, **P<0.01, #P<0.001 versus the control group. 3-MA promotes cell apoptosis and ROS production reduced by HP-Exos in DSS-induced colitis IECs. (A and B) Cell apoptosis were analysed by flow cytometry. (C-F) The expression of Bcl-2, BAX and Cleaved caspase-3 proteins were measured by WB. (H)ROS accumulation were analysed using flow cytometry. All data are means ± SDs (n = 3). *P<0.05, **P<0.01, #P<0.001 versus the control group. Discussion The number of patients with UC is increasing, which seriously affects the quality of life of patients. Thus, finding effective treatment drugs is urgent. Our results suggest that HIF-1α/BNIP3-mediated mitophagy in IECs is key for the ability of HP-Exos to alleviate UC symptoms and intestinal mucosal injury. In recent years, the ability of HP-Exos to regulate the immune microenvironment has been extensively studied. HP-Exos repair traumatic spinal cord injury by shifting microglial M1/M2 polarization28 and promoting angiogenesis and nerve regeneration through HIF-1α23. In addition, HP-Exos promoted bone fracture healing by enhancing the production of exosomal miR-126 through the activation of HIF-1α29 and facilitated cardiac repair through the miR-125b-mediated prevention of cell death in myocardial infarction30. However, very few studies have investigated the use of HP-Exos in the treatment of UC. Notably, studies have shown that HIF overexpression in human MSCs improves the healing properties of extracellular vesicles in patients with Crohn’s disease24. More importantly, we previously demonstrated that HP-Exos can effectively relieve symptoms and inhibit IEC damage in UC rats through HIF-1α. However, how HP-Exos regulate intestinal oxidative stress and apoptosis in UC is unclear. Numerous studies have shown that mitophagy is closely related to ROS and apoptosis31. Mitochondria are important signaling hubs that regulate innate and adaptive immunity in eukaryotic cells, and the occurrence of UC is closely related to changes in mitochondrial structure and function. Previous studies have shown that intestinal epithelial cells deficient in mitophagy are more vulnerable to injury, and autophagy and autophagy-related proteins have been shown to regulate epithelial apoptosis and necrosis during intestinal injury and inflammation32. In accordance with these findings, compared with normal conditions, DSS-induced mitochondrial morphological abnormalities in the intestinal epithelial cells of UC rats, including mitochondrial crista collapse and mitochondrial membrane swelling and rupture, reduced membrane potential changes by 70%33. Ginsenoside Rd inhibits DSS-induced experimental colitis in mice by promoting AMPK–ULK1–p62 axis-driven mitophagy to mediate NLRP3 inflammasome inactivation34. More importantly, MSC-Exos promote mitophagy and inhibit pyroptosis35. Here, we observed that HP-Exos markedly promoted DSS-induced mitophagy, which in turn led to the inhibition of ROS accumulation and apoptosis. Furthermore, blocking autophagy with 3-MA eliminated the effects of HP-Exos. These results indicate that mitophagy contributes to the improved effect of HP-Exos in colitis rats. The PRKN-independent mitophagy pathway, which is mostly mediated by BNIP3, is reported to protect against oxidative stress and apoptosis and restore immune balance7. HIF-1α–BNIP3-induced mitophagy is involved in the development of a variety of diseases11–13. Our previous report focused mainly on verifying the mechanism by which HP-Exos alleviate the accumulation of ROS and DNA damage in the UC intestine. In this report, a more in-depth study of the underlying mechanism was conducted. The findings demonstrated the effect of HP-Exos on intestinal mitochondrial autophagy and its relationship with HIF-1α. In the present study, our data revealed that HP-Exos regulated HIF-1α–BNIP3 pathway-mediated mitophagy, as indicated by increases in HIF-1α and BNIP3 protein levels and the LC3II/LC3I ratio but decreases in p62 levels. To investigate the role of the HIF-1α–BNIP3 pathway, we silenced HIF-1α expression in HP-Exos in vitro and used it to intervene in HT-29 cells and animals. The results revealed that knockdown of HIF-1α reversed the increased expression of HIF-1α and BNIP3 protein, increased the LC3II/LC3I ratio, and decreased the P62 level induced by HP-Exos. In addition, HP-Exos increased LC3 fluorescence intensity and mitochondrial membrane potential, increased the number of mitophagosomes, inhibited ROS accumulation, inhibited the oxidative stress response, and inhibited apoptosis both in vivo and in vitro. Therefore, our results reveal a possible mechanism of the effects of HP-Exos in UC. Many types of exosomes have been applied in clinical practice; thus, the development of more effective exosome therapies is highly important. These findings provide new insights into the mechanism underlying the effects of HP-Exos on UC. Our research has some limitations. This study does not address the potential involvement of other major mitophagy pathways, such as the PINK1/Parkin pathway. This will be the focus of our future research. Conclusions In conclusion, we demonstrated that HP-Exos inhibit ROS accumulation and oxidative stress, reduce apoptosis, and improve DSS-induced colitis symptoms and pathological mucosal damage in UC rats by regulating HIF-1α–BNIP3-mediated mitophagy. This study provides selection and basic information for identifying potential therapeutic approaches. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements This work was supported by the National Natural Science Foundation of China (No. 81774093), the provincial finance allocated the seventh batch of National Old Chinese Medicine Experts’ Academic Experience Inheritance Project (2022, No. 08.01.22028) and Research Project of Traditional Chinese Medicine of Hubei Provincial Administration of Traditional Chinese Medicine (No.ZY2025L246) and Hubei Province Shizhen Talent Work Project (No.1000000220). Author contributions F.Z., J.B.W., and Y.Y.Y. were responsible for the design, performance, and analysis of the in vitro and in vivo experiments. F.G. was responsible for the cell culture and supported the in vitro experiments. L.J.Z. wrote the manuscript. X.X.L, Z.X.S., and H.F. contributed the reagents, materials, and analytical tools. All authors have read and agreed to the published version of the manuscript. Data availability The datasets used and analysed during the current study available from the corresponding author on reasonable request. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Feng Zhu, Jingbo Wang and Yuyi Yuan These authors contribution equally this work. Contributor Information Lijuan Zhang, Email: 614365168@qq.com. Heng Fan, Email: fanheng009@aliyun.com. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement The datasets used and analysed during the current study available from the corresponding author on reasonable request.